Rivus Pharmaceuticals Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$57M
- Investors
-
6
Rivus Pharmaceuticals General Information
Description
Developer of controlled metabolic accelerators designed to improve cardio-metabolic health. The company improves cellular metabolism and treats the underlying cause of highly prevalent metabolic and cardiovascular diseases, enabling patients with oral small-molecule therapeutics that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.
Contact Information
Website
www.rivuspharma.comCorporate Office
- 501 Locust Avenue
- 3rd Floor Suite 301
- Charlottesville, VA 22902
- United States
Corporate Office
- 501 Locust Avenue
- 3rd Floor Suite 301
- Charlottesville, VA 22902
- United States
Rivus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B2) | 16-Jan-2025 | $57M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series B) | 19-Aug-2022 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 20-Jul-2021 | $35M | $35M | Completed | Clinical Trials - Phase 2 |
Rivus Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 35,056,144 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 34.15% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Rivus Pharmaceuticals Comparisons
Industry
Financing
Details
Rivus Pharmaceuticals Competitors (12)
One of Rivus Pharmaceuticals’s 12 competitors is Enterome, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enterome | Venture Capital-Backed | Paris, France | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| MaaT Pharma | Formerly VC-backed | Lyon, France | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Eligo Bioscience | Venture Capital-Backed | Paris, France |
Rivus Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rivus Pharmaceuticals Patents
Rivus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023385491-A1 | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole | Pending | 21-Nov-2022 | ||
| EP-4622963-A1 | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole | Pending | 21-Nov-2022 | ||
| US-20260098015-A1 | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole | Pending | 21-Nov-2022 | ||
| WO-2024112659-A1 | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole | Inactive | 21-Nov-2022 | ||
| WO-2024112663-A1 | Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions | Inactive | 21-Nov-2022 | A61K31/4168 |
Rivus Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rivus Pharmaceuticals Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| BB Biotech | Asset Manager | Minority | ||
| RA Capital Management | Asset Manager | Minority | ||
| Longitude Capital | Venture Capital | Minority | ||
| Medicxi Ventures (UK) | Venture Capital | Minority |
Rivus Pharmaceuticals FAQs
-
When was Rivus Pharmaceuticals founded?
Rivus Pharmaceuticals was founded in 2019.
-
Where is Rivus Pharmaceuticals headquartered?
Rivus Pharmaceuticals is headquartered in Charlottesville, VA.
-
What is the size of Rivus Pharmaceuticals?
Rivus Pharmaceuticals has 27 total employees.
-
What industry is Rivus Pharmaceuticals in?
Rivus Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Rivus Pharmaceuticals a private or public company?
Rivus Pharmaceuticals is a Private company.
-
What is the current valuation of Rivus Pharmaceuticals?
The current valuation of Rivus Pharmaceuticals is .
-
What is Rivus Pharmaceuticals’s current revenue?
The current revenue for Rivus Pharmaceuticals is .
-
How much funding has Rivus Pharmaceuticals raised over time?
Rivus Pharmaceuticals has raised $224M.
-
Who are Rivus Pharmaceuticals’s investors?
Bain Capital Life Sciences, BB Biotech, RA Capital Management, Longitude Capital, and Medicxi Ventures (UK) are 5 of 6 investors who have invested in Rivus Pharmaceuticals.
-
Who are Rivus Pharmaceuticals’s competitors?
Enterome, Vedanta Biosciences, MaaT Pharma, Seres Therapeutics, and Eligo Bioscience are some of the 12 competitors of Rivus Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
